Company / Shareholders' Equity
Bone Biologics Corp Shareholders' Equity History
FY2017-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$11.9M
FY2020
5-year range
-$11.9M / -$8.4M
FY2017-FY2020
Trend
-38.0%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Bone Biologics Corp reports negative total equity of -$12M in FY2020. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$12M in FY2020.
Declined from -$8M to -$12M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Bone Biologics Corp's shareholders' equity has declined for 3 consecutive years.
- In FY2020, shareholders' equity decreased 38.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | -$11.9M | -38.0% |
| FY2019 | -$8.6M | -2.4% |
| FY2018 | -$8.4M | -0.4% |
| FY2017 | -$8.4M | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026